Ocrevus® (ocrelizumab) Ocrevus Zunovo™ (ocrelizumab and hyaluronidase-ocsq)

Ocrevus and Ocrevus Zunovo are covered only for FDA‑approved adult indications (relapsing forms of MS including clinically isolated, relapsing‑remitting and active secondary progressive MS, and primary progressive MS) and are not covered for patients <18 or for off‑label uses. Coverage requires prescription by or consultation with an MS‑specialist neurologist, adherence to labeled dosing (Ocrevus: 300 mg ×2 then 600 mg IV every 6 months; Ocrevus Zunovo: 920 mg SC every 6 months), 12‑month authorization periods, and for relapsing forms reauthorization after ≥12 months on therapy with documented objective clinical benefit or symptom stabilization (e.g., MRI, EDSS/NEDA, relapse reduction, functional tests, or symptom improvement).

"For re-authorization (relapsing forms), the individual has been receiving Ocrevus or Ocrevus Zunovo for at least 12 months."

Sign up to see full coverage criteria, indications, and limitations.